HIV Research / Medication Access

amfAR’s policy office advocates for a strong commitment to HIV research and for funding for the National Institutes for Health. In addition, the policy office advocates for access to affordable medicines for both HIV and HCV.

Long-Acting HIV Treatment and Prevention Are Coming: Overview

Long-Acting HIV Treatment and Prevention Are Coming: From Laboratory to Marketplace

Long-Acting HIV Treatment and Prevention Are Coming: Defining the Intended Market

Long-Acting HIV Treatment and Prevention Are Coming: Assessing the Payer Landscape

Long-Acting HIV Treatment and Prevention Are Coming: Long-Acting Agents in Development for HIV Treatment and Prevention (Chart)

Curbing the HIV Epidemic by Supporting Effective Engagement in HIV Care

Lifting All Boats: The Broad Benefits of Increased Investments in HIV/AIDS Research

Is PEPFAR Funding for Key Populations Aligned with the Epidemiologic Burden?

amfAR Calls for Increase in HIV/AIDS Research Funding at National Institutes of Health

Infographic: Small Increase, Big Impact: Investing in HIV/AIDS Research Could Fund the World’s Next Medical Breakthrough

New amfAR Report Warns of Trade Agreement’s Potentially Damaging Effects on Global Public Health

Issue Brief: Trans-Pacific Partnership: Curbing Access to Medicines Now and in the Future (May 2015)